We are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality and affordable medicines. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability.
Our business segmentsWe focus on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through our key business segments.46%
of total revenue
Regional Brands- a widely diverse range of trusted medicines with strong domestic or regional presence.
28%
of total revenue
Sterile Focus Brands- comprising our branded products in anaesthetics and thrombosis therapy areas.
Manufacturing26%of total revenue
Internal and third party supply of chemical and biochemical APIs and finished dose form ("FDF") pharmaceuticals.
Our global presenceHeadquartered in South Africa, we have a strong presence in both emerging and developed markets.65%
of Commercial Pharmaceuticals revenue from emerging markets
https://www.aspenpharma.com/global-presence/
Our manufacturing capabilitiesOur manufacturing capabilities span a wide variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients ("APIs"). Our manufacturing sites hold international approvals from some of the most stringent global regulatory agencies.7
Active pharmaceutical ingredient facilities
23
Facilities
16
Finished dose form facilities
https://www.aspenpharma.com/manufacturing-capabilities/ |
Leadership reviews
CHAIRMAN'S REVIEWGROUP CHIEF EXECUTIVE'S REVIEWDEPUTY GROUP CHIEF EXECUTIVE'S FINANCIAL REVIEWChairman's reviewAspen's long-term sustainability and success will be measured by the value we deliver to society. As a manufacturer and distributor of essential medicines, Aspen is uniquely placed to make a meaningful contribution to the global goals of increasing access to high quality, affordable medicines and reducing patient inequality.Kuseni Dlamini
Chairman
Stephen Saad
Group Chief Executive
Gus Attridge
Deputy Group Chief Executive
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Aspen Pharmacare Holdings Ltd. published this content on 09 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 October 2023 10:25:22 UTC.